The ThyroSeq mutational panel and Afirma gene expression classifier (GEC) are used to risk stratify cytologically indeterminate thyroid nodules. In the current study, the authors evaluated the performance of these tests within the context of ultrasonographic features and with the incorporation of the noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) nomenclature. METHODS: The authors reviewed nodules using ThyroSeq or Afirma GEC testing. For nodules that were surgically resected, both tests were studied within the context of ultrasound findings, comparing performance stratified by the 2015 American Thyroid Association guideline (ATA 2015) sonographic patterns and assessing the positive predictive value (PPV) of these tests both including and excluding NIFTP in the malignant category. RESULTS: A total of 304 cases were identified, 119 of which were resected. All cases that met the criteria for NIFTP on excision demonstrated either high-risk mutations on ThyroSeq or a "suspicious" result on Afirma GEC. When NIFTP cases were shifted from the malignant to nonmalignant category, the PPV of "positive" tests for both ThyroSeq and Afirma GEC decreased from 42.9% to 14.3% (an absolute decrease of 28.6%) and 30.1% to 25.3% (an absolute decrease of 4.8%), respectively. No cases of malignancy were found in the ATA 2015 "very low suspicion" group, even with a "suspicious" Afirma GEC result. CONCLUSIONS: Both the ThyroSeq and Afirma GEC tests demonstrated decreases in the PPV when NIFTP was considered nonmalignant. In the era of NIFTP, a "positive" test result for either the Afirma GEC or ThyroSeq should be interpreted in light of clinical factors and should not exclude conservative (ie, lobectomy) surgical management. ATA 2015 "very low suspicion" nodules, even with "suspicious" Afirma GEC results, were not found to demonstrate malignancy in this series. Cancer Cytopathol
INTRODUCTION
The indeterminate categories within the Bethesda System (atypia of undetermined significance/follicular lesion of undetermined significance and follicular neoplasm/suspicious for follicular neoplasm) complicate clinical decision making within the 2015 American Thyroid Association guideline (ATA 2015) framework. Thyroid nodules that fall into these categories have been assigned management recommendations to either proceed to surveillance or diagnostic surgery. [1] [2] [3] Although immunohistochemical stains 4 and repeat ultrasound-guided fine-needle aspiration biopsy (FNA) occasionally can aid in decision making, 5 Bethesda category III and IV thyroid nodules continue to challenge cytopathologists and clinicians alike, creating great excitement around molecular mutational panels. Two of the biggest players in molecular testing are the ThyroSeq mutational panel and the Afirma gene expression classifier (GEC) (Veracyte Inc, South San Francisco, California). Published data regarding the performance of the ThyroSeq V2 at the University of Pittsburgh Medical Center for the prediction of malignant potential of thyroid nodules reveals a positive predictive value (PPV) of 76.9% and a negative predictive value (NPV) of 97.2%. 6 Performance data regarding the Afirma GEC collected from a multicenter study for Bethesda category III and IV lesions demonstrated NPVs of 95% and 94%, respectively. 7 A PPV of 35% was demonstrated in a recent publication involving patients from the study institution, 8 similar to that reported in a validation study by Alexander et al. 7 With the introduction of the noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) terminology, early studies have demonstrated a decreased risk of malignancy (ROM) in The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) diagnostic groupings, especially among the indeterminate categories. 9, 10 In a cohort of indeterminate Bethesda category III and IV thyroid nodules with suspicious Afirma GEC results, the noninvasive follicular variant of papillary thyroid carcinoma accounted for approximately 64% of carcinomas. 11 In another series, reclassification of the noninvasive follicular variant of papillary thyroid carcinoma as NIFTP resulted in an overall malignancy rate of 13.6% for Bethesda category III lesions and 15.1% for Bethesda category IV lesions. 9 NIFTP and molecular testing have been incorporated into the latest edition of TBSRTC as well. 12 Because lesions in these indeterminate categories are the ones most likely to undergo molecular testing, it is likely that the shift to NIFTP terminology will reduce the ROM for molecular "positive" results as well.
To the best of our knowledge, little work has been done to date to assess nodule characteristics (size, ultrasound features) within the context of molecular test results. Given the changing ROM for mutations associated with thyroid lesions, further studies are needed to better characterize the clinical significance of mutational panel findings on FNA specimens, taking into account these nodule characteristics.
MATERIALS AND METHODS
After institutional review board approval, we performed a retrospective study of thyroid nodule cytology cases tested in adult patients (those aged 18 years) at the study institution using ThyroSeq mutational analysis panels (including 7-gene ThyroSeq and ThyroSeq V2) or the Afirma GEC between June 2012 and August 2016. For each case, the following information was collected: age, sex, cytology diagnosis, diagnosis at the time of surgical resection, and molecular test results. Thyroid FNA at the study institution, which takes place largely under ultrasound guidance, is performed by board-certified radiologists, endocrinologists, surgeons, and cytopathologists. TBSRTC is used to report the results of thyroid FNA samples. We generally reserve molecular testing for repeat indeterminate nodules. 1 This practice pattern is designed to reduce the number of molecular studies; because some of the indeterminate diagnoses are due to technical factors, the diagnosis may be benign at the time of repeat FNA. The choice of specific molecular test (ie, Afirma GEC vs ThyroSeq) is made by the referring clinician based on the clinical scenario. Nodules were excluded if the samples had insufficient material for successful testing or if results revealed parathyroid tissue. Surgical pathology results were reviewed by endocrine pathology specialists for resected nodules. Cases of encapsulated follicular variant without capsular or lymphovascular invasion were rereviewed to identify those lesions that would meet the criteria for NIFTP. These NIFTP lesions underwent additional consensus review to confirm that diagnostic criteria described by Nikiforov et al were met. 6 For resected nodules, nodule size and ultrasound features were assessed. Ultrasound reports for these nodules were reviewed to assign a sonographic pattern according to the ATA 2015, whenever possible. The size and sonographic description of these nodules were reviewed to determine whether the nodule met the ATA 2015 criteria for biopsy. 
RESULTS
Over the study period, samples from a total of 304 nodules from 289 patients were sent for molecular testing. Of these, FNA samples from 97 thyroid nodules were sent for ThyroSeq molecular testing and 207 samples were sent for Afirma GEC molecular testing. The patient demographics of the 2 cohorts were comparable, both with a female predominance ( Table 1 ). The majority of nodules sent for molecular testing in both groups were in the indeterminate Bethesda categories, and the majority of the nodules (84 of 97 nodules in the ThyroSeq cohort and 204 of 207 nodules in the Afirma GEC cohort) were repeat indeterminate nodules. There were a few nodules in the TBSRTC benign category that were sent for molecular testing due to a prior
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In the Afirma GEC cohort, of the 207 nodules that were tested, approximately one-half (105 nodules; 51%) were "benign" by GEC and the other one-half (102 nodules; 49%) were "suspicious" on GEC. The majority of patients with the Afirma GEC "benign" nodules did not undergo surgery, and all 13 cases (12%) that underwent surgical excision demonstrated benign findings. There were no cases of NIFTP in the Afirma GEC "benign" cohort that went to surgical resection. The majority of patients with the Afirma GEC "suspicious" cases (81%) underwent surgical resection. Of the Afirma GEC "suspicious" cases that went to surgery, the majority (70%) demonstrated benign findings. A total of 21 cases (21%) demonstrated malignancy, and 4 cases (4%) met the criteria for NIFTP (Fig. 1) .
In the ThyroSeq cohort, of the 97 nodules that were tested, the majority (83%) did not demonstrate high-risk (HR) mutations. The majority of the patients with these nodules without HR mutations (59%) did not undergo surgery. Of the HR mutation-negative cases that went to surgery, there were no NIFTPs and only 1 case demonstrated a malignancy, which was a minimally invasive follicular carcinoma. The majority of the patients with nodules that were positive for HR mutations (82%) underwent surgical resection. Of these surgically resected cases, the majority (57%) demonstrated benign findings. Two cases (14%) demonstrated malignancy, and 4 cases (29%) met the criteria for NIFTP (Fig. 2) . Table 2 shows the distribution of TBSRTC diagnostic categories, surgical follow-up, and PPV with and without cases of NIFTP for cases with a "positive" test result (either a HR mutation identified on ThyroSeq or a "suspicious" Afirma GEC result). All of the cases that were found on surgical resection to meet the criteria for NIFTP either had a "suspicious" Afirma GEC result or a ThyroSeq panel demonstrating HR mutations. All cases of NIFTP were in the indeterminate categories on cytology. When NIFTP was removed from the malignant category, there were decreases in the PPV of a positive test noted for both Afirma GEC and ThyroSeq. The PPV for a positive HR mutation found on ThyroSeq decreased from 42.9% to 14.3%, an absolute decrease of 28.6%. The PPV of a "suspicious" Afirma GEC result decreased from 30.1% to 25.3%, an absolute decrease of 4.8% (Fig. 3) . For patients with nodules who underwent surgical resection, an ATA 2015 sonographic pattern category was able to be assigned based on the ultrasound reports for 70 of the cases tested by Afirma GEC and 26 of the cases tested by ThyroSeq. For the Afirma GEC cohort, the highest overall ROM was in the patients with both a "high suspicion" ATA 2015 sonographic pattern and a "suspicious" Afirma GEC result, with 4 of 9 patients (44%) found to have a malignancy on surgical resection. None of the 4 nodules with a "very low suspicion" ATA 2015 sonographic pattern were found to be malignant or NIFTP at the time of surgical resection, despite 3 of 4 of these nodules having a "suspicious" Afirma GEC result. For the ThyroSeq cohort, the highest overall ROM or NIFTP was found for patients with both a "high suspicion" ATA 2015 sonographic pattern and a HR mutation detected; however, there was only 1 patient in this category who was found to have a NIFTP. The presence of a HR mutation on ThyroSeq was found to be associated with malignancy or NIFTP in 4 of 6 patients (66.7%) with a "lowsuspicion" ATA 2015 sonographic pattern. In the sonographically intermediate-and low-suspicion categories, a "negative" result on molecular testing (either no HR mutations by ThyroSeq or a "benign" Afirma GEC result) was associated with benign pathology on surgical resection for 22 of 23 cases. The single malignancy in this group was a minimally invasive follicular carcinoma with an intermediate-suspicion ATA 2015 sonographic pattern and no HR mutations found on the 7-gene ThyroSeq panel (Table 3) .
Nodule size for resected nodules ranged from 1.1 to 5.3 cm for the ThyroSeq cohort and 0.7 to 6.3 cm for the Afirma GEC cohort. Of the Afirma GEC cohort, 3 of these nodules measured <1 cm in size. Based on the size and ATA 2015 sonographic pattern, 60 of 70 nodules in the Afirma GEC cohort (85.7%) and 23 of 26 nodules in the ThyroSeq cohort (88.5%) met the ATA 2015 criteria for biopsy. The majority of the nodules that did not meet the ATA 2015 criteria for biopsy were biopsied before the 2015 guidelines. The other nodules that did not meet the criteria were biopsied due to family history or other clinical factors. In both the Afirma GEC and ThyroSeq groups, when molecular test results were not considered, rates of malignancy/NIFTP were similar for nodules that met and did not meet the ATA 2015 criteria for biopsy (range, 25.0%-30.0%). The percentage of malignant cases in the Afirma GEC "suspicious" category was similar regardless of whether the nodules met or did not meet ATA 2015 criteria for biopsy (29.4% and 33.3%, respectively). The percentage of malignant cases was higher for nodules with HR mutations by ThyroSeq both for nodules that did and did not meet the ATA 2015 criteria for biopsy; however, only 1 case was present that had HR mutations and did not meet the ATA 2015 criteria for biopsy (Table 4) .
DISCUSSION
The goal of the molecular testing of cytological samples from indeterminate thyroid nodules is to add evidence in support of or against the need for surgical treatment and the extent of surgery (lobectomy or total thyroidectomy). Molecular testing offers additional prognostic evidence in terms of ROM that is intended to help endocrinologists and surgeons decide between lobectomy and total thyroidectomy for patients with cytologically indeterminate thyroid nodules or, conversely, no surgery at all.
Currently published ROMs with results of these molecular tests were established before the nomenclature revision of the encapsulated follicular variant of papillary thyroid carcinoma to NIFTP. Removal of the word "cancer" from this entity's name reflects the indolent behavior of this lesion. Just as this nomenclature revision alters ROM in different categories in TBSRTC, especially the indeterminate categories, 9,10 molecular testing panels are likely to note a decrease in the ROM associated with "positive" results.
In light of the likely decrease in the ROM for mutations commonly associated with thyroid cancer due to the establishment of the NIFTP nomenclature, it is important to broaden validation of molecular panels to include this entity. Validation studies including updated classifications of thyroid tumors will result in more accurate PPVs and 
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NPVs of the molecular panels. The impact of the improved predictive values hopefully will contribute to improved prognostication for patients in whom thyroidectomy is being considered.
The findings of the current study support predictions that NIFTP decreases the risk of malignancy for a "positive" result for both the Afirma GEC and ThyroSeq, thereby adding to the limited literature regarding this topic. Table 5 summarizes the distribution of cases with "suspicious" Afirma GEC or HR mutations on ThyroSeq in the current study alongside the existing literature. 11, [13] [14] [15] The PPV of a "suspicious" Afirma GEC if NIFTP is not removed from the malignant category ranges from 30.1% to 39.3% for studies that specifically looked at GEC results in the context of NIFTP. If NIFTP is removed from the malignant category, the PPV ranges from 12.7% to 29.9%, with absolute decreases in PPV ranging from 4.8% to 22.2%. The decrease in PPV for a "suspicious" Afirma GEC result in our experience was lower than in other studies at 4.8%, which reflects the smaller number of NIFTPs in the current study cohort.
To our knowledge, independent studies of ThyroSeq are limited, with only 1 other published study assessing the performance of ThyroSeq with regard to NIFTP. 16 Although that study had a PPV for HR mutations that was similar to our experience if NIFTP was included in the malignant group (42.4% vs 42.9%), when NIFTP was removed, the PPV in the current study dropped much more, to 14.3% versus 33.3%. Both studies were limited by the relatively small numbers of patients who had HR mutations on ThyroSeq. The differences in the impact of the NIFTP classification on the PPV across studies most likely is due to several factors, including variations in the institutional prevalence of malignancy as well as NIFTP.
To the best of our knowledge, none of these other studies compared molecular testing modalities within the same institution, which we have done herein. It is interesting to note that in our experience, the impact of the NIFTP reclassification was greater in the ThyroSeq cohort compared with the Afirma GEC cohort, with the majority of the "malignancies" fitting the criteria for reclassification as NIFTP. This most likely is due to the fact that, as we and others have previously described, 2, 15, 17 NIFTPs often demonstrate RAS mutations, which were categorized as HR by the ThyroSeq panel. In addition, because the choice of molecular testing platform was not randomized but rather was based on clinician choice after taking into account patient and nodule characteristics, there may be other factors contributing to these differences in test performance that were not captured in the current study. In addition, in the current study, we examined the size and ultrasound features of nodules in conjunction with molecular test results to assess whether these additional nodule characteristics impact the ROM at the time of surgical resection. Although these data are limited by the small sample size, there are some interesting observations. First, for nodules with a "very low suspicion" ATA 2015 sonographic pattern, we found no malignancies in the cohort that underwent surgical resection, despite 3 of these 5 nodules having a "positive" result on molecular testing (all 3 had "suspicious" Afirma GEC results). The number of cases in this category was low, which is to be expected because these nodules generally should undergo less testing and less surgical resection given the low ROM. Conversely, for nodules with a "high suspicion" ATA 2015 sonographic pattern, including nodules that already had a high ROM and a positive test result on either ThyroSeq or Afirma GEC testing potentially adds to their ROM. For nodules that are considered to be of intermediate or low suspicion by ATA 2015 criteria, a "negative" result (either no HR mutations by ThyroSeq or a "benign" Afirma GEC result) generally was associated with benign pathology on surgical resection.
Limitations of the current study largely are those shared by other retrospective "real-world" studies of molecular test performance. We do not have surgical follow-up for all cases that were sent for molecular testing. Although the majority of patients with a positive test result on both the Afirma GEC and ThyroSeq (approximately 80%) underwent surgery, it was not 100%, and therefore the PPV was only for these patients with resected nodules and not all patients. For the ThyroSeq cohort, we had relatively few cases that demonstrated HR mutations, reflecting that the majority of the cases in the current study (83%) were negative for mutations. We had a small number of NIFTP cases, which is in keeping with other studies demonstrating that a diagnosis of NIFTP is relatively rare if strict criteria are applied for diagnosis. 9, 10, 18 With regard to our assessment of ultrasound features and size within the context of molecular testing, because the current study is pathology focused, we reviewed ultrasound reports to assign nodules to ATA 2015 sonographic patterns rather than reviewing the ultrasound images themselves. This further limited our numbers, because not all nodules had documented ultrasound findings that allowed for categorization. As such, particularly for the ThyroSeq cohort, the sample size in several categories was small. We chose to use the sonographic patterns described in the ATA 2015 guidelines and incorporate the impact of nodule size by assessing whether the nodule met the criteria for biopsy. Because these guidelines are widely used and accepted, we believed that using these categories would be most meaningful from the perspective of real-world practice. Because we were limited to patients with surgical follow-up, the results of the current study were biased toward patients whose nodule characteristics, molecular results, and other clinical findings led to surgical resection, which likely skewed our sample toward greater numbers of malignant cases. Our experience supports that NIFTP lesions largely are associated with positive ThyroSeq and Afirma GEC results when FNA biopsies are cytologically indeterminate. Given the complex cytologic and ultrasonographic differentiation of these lesions, ThyroSeq and Afirma GEC testing of nodules is helpful for providing results, thereby allowing patients to proceed with surveillance rather than surgery if they receive a negative result (no mutations or low-risk mutation[s] found) within the context of an indeterminate nodule by repeat FNA. Conversely, if a HR mutation is detected (as determined by ThyroSeq), or a suspicious result returned by Afirma GEC, the findings of the current study support that these results should not necessarily be taken as evidence of carcinoma. However, this is not to say that these results are necessarily "false-positives" for the cases classified on surgical resection as NIFTPs. This is an important point to remember when considering the results of all of these studies: to our current understanding, NIFTP is a lesion that, although indolent, nevertheless warrants at least conservative surgical excision, both for diagnosis and management. 18, 19 Therefore, in the case of NIFTP, the Afirma GEC and ThyroSeq tests still are successfully identifying patients who would potentially still require surgical management. Given current concerns regarding the overtreatment of thyroid nodules, the ATA 2015 guidelines allow for more conservative surgical excision among patients with low-risk tumors. 2 The data from the current study and that of other studies have demonstrated that a "positive" result on molecular testing does not necessarily preclude proceeding with conservative excision, particularly for those cases that on ThyroSeq demonstrate isolated RAS mutations. Within the context of sonographic findings, with regard to nodules demonstrating an ATA 2015 "very low suspicion" sonographic pattern, although few of the patients with these nodules go on to undergo surgery, in the current series there were no malignancies even with a "suspicious" Afirma GEC finding, thereby suggesting that the usefulness of molecular testing in these nodules may be low. For the cases with ATA 2015 sonographic patterns of low or intermediate suspicion, a "negative" result on molecular testing (either no HR mutations by ThyroSeq or a "benign" Afirma GEC result) may be reassuring. Given the relatively low PPV of both modalities in the current series, the usefulness of both the ThyroSeq and Afirma GEC tests may lie in their NPV. Given that nodules with negative results generally are not resected, as the number of patients evaluated with these tests grows, long-term clinical follow-up studies are needed to address the true NPV of these tests. As our knowledge of the biology and prognosis of thyroid nodules continues to evolve, so must our understanding of molecular testing results. Given the vernacular of TBSRTC, pathologists and clinicians tend to interpret both cytology and molecular test results within the context of their corresponding ROM, with a binary categorization as either benign or malignant. However, due to the broad spectrum of behavior demonstrated by thyroid neoplasms, it may prudent to reconsider a more nuanced stratification of these lesions in terms of management decisions. For example, the categorization of mutations in terms of requiring total thyroidectomy versus conservative surgical resection for definitive classification and management, as opposed to lesions we can confidently observe, would aid in the interpretation of molecular test results on cytology specimens by clinicians so that they achieve their original aim of guiding treatment decisions for patients with nodules of indeterminate categories with currently limited recommendations. Additional multi-institutional studies are needed to characterize the relationship between ultrasonographic findings, biological behavior, and molecular changes to better our understanding of the pathogenesis and prognosis of thyroidal neoplasms.
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